CN103638563B - A kind of biological fluid of biological fibrin glue - Google Patents
A kind of biological fluid of biological fibrin glue Download PDFInfo
- Publication number
- CN103638563B CN103638563B CN201310619137.0A CN201310619137A CN103638563B CN 103638563 B CN103638563 B CN 103638563B CN 201310619137 A CN201310619137 A CN 201310619137A CN 103638563 B CN103638563 B CN 103638563B
- Authority
- CN
- China
- Prior art keywords
- biological
- fibrin glue
- chitosan
- parts
- hemostasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 title claims abstract description 20
- 239000013060 biological fluid Substances 0.000 title claims abstract description 12
- 229920001661 Chitosan Polymers 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000661 sodium alginate Substances 0.000 claims abstract description 15
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 15
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 229920002472 Starch Polymers 0.000 claims abstract description 11
- 239000008107 starch Substances 0.000 claims abstract description 11
- 235000019698 starch Nutrition 0.000 claims abstract description 11
- 238000001816 cooling Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000023597 hemostasis Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 231100000614 poison Toxicity 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 3
- 206010030113 Oedema Diseases 0.000 abstract description 2
- 208000004880 Polyuria Diseases 0.000 abstract description 2
- 230000035619 diuresis Effects 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract description 2
- 239000003440 toxic substance Substances 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 abstract description 2
- 206010052428 Wound Diseases 0.000 description 11
- 108010088751 Albumins Proteins 0.000 description 10
- 102000009027 Albumins Human genes 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 239000003292 glue Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000194025 Streptococcus oralis Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229940058573 b-d glucose Drugs 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229950007432 endomycin Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- -1 polysaccharide carbohydrate Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a kind of biological fluid of biological fibrin glue, it comprises the composition of following parts by weight: sodium alginate 90-100 part, chitosan 80-110 part, food starch 5-100 part, card ripple 5-100 part, water 1000g-1500 part.The present invention coordinates and utilizes heat-clearing and toxic substances removing, inducing diuresis to remove edema and have hemostasis, Promotive union, prevent the biology of adhesion, and coordinate some biologic formulation, sterilization can be realized, have hemostasis, Promotive union fast, prevent effect of adhesion and antiinflammatory, for hemostasis after use biological fibrin glue operative treatment, Promotive union, there is good curative effect.
Description
Technical field
The present invention relates to biological field, especially a kind of biological fibrin glue biological fluid.
Background technology
Fibrin Glue Problems existing, the simplification of donor source as different in albumin glue, ingredient origin, application and effectiveness, hemostatic function limit to, the selection etc. of mechanical strength and fibrinolytic inhibitor.Fibrin Glue used clinically can be divided into business pooled plasma type and single donator type by its plasma donor prepared.Current use is business pooled plasma type more widely, and reason is that mixed type albumin glue has better mechanics, biology and rheological property.The ingredient origin of albumin glue has two latencies here, and they are all relevant with use animal immunogenic material, mainly thrombin of beef and aprotinin.
Summary of the invention
The invention provides and a kind of there is good antiinflammatory, hemostasis, Promotive union, prevent the biological fluid of the biological fibrin glue of effect of adhesion and sterilization.
The present invention is achieved by the following technical solutions: a kind of biological fluid of biological fibrin glue, and it comprises the composition of following parts by weight: sodium alginate 90-100 part, chitosan 80-110 part, food starch 5-100 part, card ripple 5-100 part, water 1000-1500 part.
Preferably, it comprises the composition of following parts by weight: sodium alginate 95 parts, chitosan 100 parts, food starch 50 parts, 30 parts, card ripple, 1200 parts, water.
The preparation method of the biological fluid of above-mentioned biological fibrin glue, is characterized in that, takes each components dissolved by weight ratio in water, and 70-90 degree stirs 20-40 minute, packs after cooling.
Advantage of the present invention is: coordinate and utilize heat-clearing and toxic substances removing, inducing diuresis to remove edema and have hemostasis, Promotive union, prevent the biology of adhesion, and coordinate some biologic formulation, sterilization can be realized, have hemostasis, Promotive union fast, prevent effect of adhesion and antiinflammatory, have hemostasis, Promotive union, prevent the functions such as adhesion and biological fibrin glue to have good curative effect.
Detailed description of the invention
The biological fluid of biological fibrin glue of the present invention, it comprises the composition of following parts by weight: sodium alginate 90-100 part, chitosan 80-110 part, food starch 5-100 part, card ripple 5-100 part, water 1000-1500 part.
Preferably, it comprises the composition of following parts by weight: sodium alginate 95 parts, chitosan 100 parts, food starch 50 parts, 30 parts, card ripple, 1200 parts, water.
The preparation method of the biological fluid of above-mentioned biological fibrin glue, takes each components dissolved by weight ratio in water, and 70-90 degree stirs 20-40 minute, packs after cooling.
Sodium alginate has another name called sodium alginate, seaweed gel, Algin, alginate, is by the natural polysaccharide carbohydrate extracted in Thallus Laminariae (Thallus Eckloniae).Be widely used in the products such as food, medicine, weaving, printing and dyeing, papermaking, daily-use chemical industry, as uses such as thickening agent, emulsifying agent, stabilizing agent, binding agent, sizing agents.Since the eighties, sodium alginate obtains new expansion in food applications.Sodium alginate is not only a kind of safe food additive, and can be used as the base material of bionic foods or remedy diet, because it is actually a kind of native cellulose, the absorption of fat sugar and cholate can be slowed down, have reduce serum cholesterol, the effect of triglyceride and blood glucose in blood, can the modern disease such as prophylaxis of hypertension, diabetes, obesity.It can suppress poisonous metal as the accumulation in vivo such as strontium, cadmium, lead in intestinal, exactly because these important function of sodium alginate, is at home and abroad day by day valued by the people.Japanese calls the food being rich in sodium alginate " life prolonging food ", and American is then called " marvellous food additive ".Purposes: stabilizing agent, thickening agent, make artificial semipermeable membrane, mordant.Biochemical level is used for fixed cell, enzyme; As sodium alginate method immobilized glutamate decarboxylase.
Chitosan (chitosan) is that the chitin (chitin) extensively existed by nature obtains through deacetylation, chemical name is Chitosan (1-4)-2-amino-B-D glucose, from 1859, after first Frenchman Rouget obtains chitosan, the biological functionality of this natural polymer and the compatibility, blood compatibility, safety, the premium properties such as microbic resolvability are by all trades and professions extensive concern, at medicine, food, chemical industry, cosmetics, water treatment, METAL EXTRACTION and recovery, the applied research of the numerous areas such as biochemistry and biomedical engineering achieves major progress.For patient, chitosan blood fat reducing, hypoglycemic effect have research report.Under given conditions; chitosan can be hydrolyzed, alkylation, acyl group, carboxy methylation, sulfonation, nitrated, halogenation, oxidation, reduction, the chemical reaction such as condensation and complexation; the various chitosan derivatives with different performance can be generated, thus expand the range of application of chitosan.
Its physiologically active: control cholesterol, Antibacterial activity, prevention and corntrol hypertension, absorption and excretion heavy metal and there is immune effect.
Chitosan has higher protein adsorption ability; Under the effect of digestive enzyme (lysozyme lysozyme, kitinase), chitosan tool degradability; Chitosan is easy to be processed into line, is applicable to the medical material making wire or lamellar; Chitosan has affinity and dissolubility, is applicable to produce each analog derivative; Chitosan has higher chemism; The retentiveness of chitosan is high; In serum, the easy degraded and absorbed of chitosan; Chitosan has higher biological degradability; Chitosan shows the effect selectively highly suppressing Streptococcus oralis growth, does not affect the growth of other beneficial bacterias simultaneously.
Chitosan is in medical application: promote blood coagulation and wound healing, as medicine sustained-release matrix, for artificial tissue and organ, there is immunoregulatory activity.
Starch: the high polymer pharmaceutic adjuvant that can be regarded as glucose, filler and disintegrating agent etc.As disintegrating agent (Disintegrants): disintegrating agent makes tablet split rapidly the material being broken into fine particle in gastro-intestinal Fluid, except slow (control) is released except the tablet of sheet and some specific use, in general tablet, all disintegrating agent should be added.Because they have very strong water swellability, the adhesion of tablet can be disintegrated, tablet be split from an overall tablet and is broken into many tiny granules, realize the disintegrate of tablet, so be extremely conducive to dissolving and the absorption of principal agent in tablet.Starch is a kind of disintegrating agent the most classical, water content is below 8%, water absorption is comparatively strong and have certain dilatancy, comparatively be applicable to the tablet of water-insoluble or microsolubility medicine, but it is poor to the disintegration of soluble drug, this is because soluble drug meets water dissolution produce concentration difference, the water outside tablet is not easily passed through inside that solution aspect penetrates into tablet, hinders the imbibition of tablet internal starch.
Embodiment 1
Take each component by weight ratio: sodium alginate 95g, chitosan 100g, food starch 50g, card ripple 30g, be dissolved in 1200g water, 80 degree of stirrings 20 minutes, pack after cooling.
The performance of product, can be drawn by following several groups of test datas:
The commercially available constituent of table 1
Table 2 Fibrin Glue compares (s) with thrombin bleeding stopping period
The postoperative section healing state of table 3 compares
Table 4 Fibrin Glue compares (s) with thrombin bleeding stopping period
Biological fibrin glue of the present invention is identical with original bioresorbable albumin glue, the bioprotein collagen of absorption is adopted to make completely, there is biological activity identical with bioresorbable albumin glue, also have protozoa absorbability albumin glue so advantage, as without antibacterial endomycin, apyrogeneity, virus-free, have no side effect, can be absorbed completely by human body, therefore, when filling wound for biological fibrin glue, can be stayed in human body and need not be taken out, avoid patient by rescue and therapeutic process in secondary bear affliction.And due to albumin glue of the present invention be that the albumen glueballs of all size, albumin glue are aqueous; Therefore, fill all size, shape wound time be easy to operation, filling speed is fast, and particularly for the open wound of area, its advantage is more obvious.Can platelet be impelled to form tampon rapidly in 30 seconds, reach the effect of hemostasis; Bioprotein collagen wherein, can divide a word with a hyphen at the end of a line by inductive factor, is conducive to the regeneration of damaged tissues, impels the healing of wound, and in the agglutination of wound, is progressively absorbed by the body, and therefore albumin glue of the present invention is applicable to the various wound hemostasis of clinical departments; As the human tissue injury that various operation or wound cause; The situations such as daily wound, athletic injury, accidental wound, war wound first aid hemostasis or for impelling the nursing of wound healing.Because this albumin glue both had definite shape, its shape capability is very strong again, therefore, directly clogs wound when first aid, does not need to reduce it, the pretreatment such as molding.
The primary clinical use of table 5FS
Above-described embodiment is only for illustration of technological thought of the present invention and feature, its object is to enable those skilled in the art understand content of the present invention and implement according to this, only can not limit the scope of the claims of the present invention with the present embodiment, namely the equal change done of all disclosed spirit or modification, still drop in the scope of the claims of the present invention.
Claims (3)
1. a biological fluid for biological fibrin glue, is characterized in that, it is grouped into by the one-tenth of following parts by weight: sodium alginate 90-100 part, chitosan 80-110 part, food starch 5-100 part, card ripple 5-100 part, water 1000-1500 part.
2. the biological fluid of biological fibrin glue according to claim 1, is characterized in that, it is grouped into by the one-tenth of following parts by weight: sodium alginate 95 parts, chitosan 100 parts, food starch 50 parts, 30 parts, card ripple, 1200 parts, water.
3. a preparation method for the biological fluid of biological fibrin glue as claimed in claim 1, is characterized in that, takes each components dissolved by weight ratio in water, and 70-90 degree stirs 20-40 minute, packs after cooling.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310619137.0A CN103638563B (en) | 2013-11-28 | 2013-11-28 | A kind of biological fluid of biological fibrin glue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310619137.0A CN103638563B (en) | 2013-11-28 | 2013-11-28 | A kind of biological fluid of biological fibrin glue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103638563A CN103638563A (en) | 2014-03-19 |
| CN103638563B true CN103638563B (en) | 2015-09-02 |
Family
ID=50243932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310619137.0A Expired - Fee Related CN103638563B (en) | 2013-11-28 | 2013-11-28 | A kind of biological fluid of biological fibrin glue |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103638563B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106982766B (en) * | 2017-04-01 | 2020-12-18 | 浙江海洋大学 | A method for predicting the spawning period of Portunus trituratus |
| CN107308489A (en) * | 2017-05-17 | 2017-11-03 | 广西品位生物科技有限公司 | A kind of biological fluids of biogum |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1330389C (en) * | 2003-03-05 | 2007-08-08 | 朱晓明 | Hematostatic gel |
| CN1235646C (en) * | 2003-11-03 | 2006-01-11 | 刘永庆 | Method for preparing multifunctional biological repair material |
| CN101524543A (en) * | 2008-03-07 | 2009-09-09 | 大连永兴生物医药孵化器有限公司 | Hemostatic gel film agent |
| CN101716366A (en) * | 2009-12-17 | 2010-06-02 | 天津大学 | Biocolloid hemostatic prepared by aldehyde-modified sodium alginate and amine-modified gelatine |
| WO2013062994A1 (en) * | 2011-10-25 | 2013-05-02 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating full thickness burn injuries |
-
2013
- 2013-11-28 CN CN201310619137.0A patent/CN103638563B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103638563A (en) | 2014-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103349791B (en) | Novel microporous medical hemostatic material and preparation method thereof | |
| Bilgili et al. | Hemostatic efficacy of Ankaferd Blood Stopper® in a swine bleeding model | |
| CN101584876B (en) | Medical compound micropore polysaccharide and application thereof | |
| CN105001434B (en) | Multi-functional hemostatic microsphere of one class based on chitosan | |
| CN103816562B (en) | A rapid hemostasis product for war wounds and its preparation method | |
| CN108926735B (en) | Modified chitosan-alginate-dragon's blood composite nano-hemostatic material and preparation method thereof | |
| CN104147108B (en) | Bacteriostatic gel containing brown alga oligose | |
| CN110755675A (en) | Composite biological paste capable of rapidly stopping bleeding and preparation method and application thereof | |
| CN103638563B (en) | A kind of biological fluid of biological fibrin glue | |
| CN108159074A (en) | It is a kind of for hypochlorous acid chitosan Wound-protection liquid of wound healing and preparation method thereof | |
| CN107412843B (en) | Starch-based microporous hemostatic material with antibacterial property and preparation method and application thereof | |
| CN109589446A (en) | A kind of absorbable biological hemostatic material and preparation method thereof | |
| CN104874011A (en) | Hemostatic and preparation method and application thereof | |
| CN105477679A (en) | Polysaccharide crosslinking based quick chitosan hemostatic cotton | |
| CN106975098A (en) | A kind of complex polysaccharide hemostatic composition and preparation method and application | |
| CN105412977A (en) | Chitosan wound dressing | |
| CN107412840A (en) | It is a kind of that there is the hemostatic composition for stablizing drug effect | |
| CN110755674B (en) | Hemostatic powder and preparation method thereof | |
| CN116113449A (en) | Advanced Dressing Containing Porous Polycaprolactone Membrane | |
| CN105727345A (en) | Absorbable hemostasis membrane material and preparation method thereof | |
| CN109731128B (en) | Absorbable and degradable biocompatible hemostatic material and preparation method thereof | |
| WO2017060821A1 (en) | Hemostatic composition | |
| CN107715167A (en) | Chitosan-based hemostatic paste and preparation method as bone wax substitute | |
| CN107041965A (en) | A kind of efficient styptic sponge and preparation method thereof | |
| CN103623413B (en) | Preparation method and application of controlled release carrier material of sucrose ester |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160427 Address after: 100000 Beijing city Chaoyang District Lu Village Shibalidian Township No. 23 A District No. 232 Patentee after: Beijing Tak Lung Biotechnology Co., Ltd. Address before: 301500, Tianjin County, Ninghe County, West Village, 500 meters north side of the village outside Patentee before: TIANJIN DETAIRAN BIO-PHARMACEUTICAL CO., LTD. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150902 Termination date: 20161128 |